advertisement
Abstract #99226 Published in IGR 22-4
Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)
Fastner G; Reitsamer R; Gaisberger C; Hitzl W; Urbański B; Murawa D; Matuschek C; Budach W; Ciabattoni A; Reiland J; Molnar M; Vidali C; Schumacher C; Sedlmayer F; On Behalf Of The Hiob Trialist GroupCancers 2022; 14:
BACKGROUND AND PURPOSE: To investigate intraoperative electron radiation therapy (IOERT) as a tumor bed boost during breast conserving surgery (BCS) followed by hypofractionated whole breast irradiation (HWBI) on age-correlated in-breast recurrence (IBR) rates in patients with low- to high-risk invasive breast cancer. MATERIAL AND METHODS: BCS and IOERT (11.1 Gy) preceded a HWBI (40.5 Gy) in 15 fractions. Five-year IBR-rates were compared by a sequential ratio test (SQRT) with best evidences in three age groups (35-40 y and 41-50 y: 3.6%, >50 y: 2%) in a prospective single arm design. Null hypothesis (H0) was defined to undershoot these benchmarks for proof of superiority. RESULTS: Of 1445 enrolled patients, 326 met exclusion criteria, leaving 1119 as eligible for analysis. After a median follow-up of 50 months (range 0.7-104), we detected two local recurrences, both in the age group >50 y. With no observed IBR, superiority was demonstrated for the patient groups 41-50 and >50 y, respectively. For the youngest group (35-40 y), no appropriate statistical evaluation was yet possible due to insufficient recruitment. CONCLUSIONS: In terms of five-year IBR-rates, Boost-IOERT followed by HWBI has been demonstrated to be superior in patients older than 50 and in the age group 41-50 when compared to best published evidence until 2010.
Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, 5020 Salzburg, Austria.
Full article